Gary Francis GlaxoSmithKline Breen

New process for production of pleuromutilinderivaten

Gary Francis GlaxoSmithKline Breen, Michael Anthony Forth, Susan Shumei Hu Kopelman, 2004 .

The Development of a Manufacturing Route for the GPIIb/IIIa Receptor Antagonist SB-214857-A. Part 2: Conversion of the Key Intermediate SB-235349 to SB-214857-A

Gary Francis GlaxoSmithKline Breen, A. Wells, J. S. Carey, 2003 .

Industrial Hydrolases and Related Enzymes

Roger M. Howard, Gary Francis GlaxoSmithKline Breen, Rebecca E. Meadows, 2012 .

Synthetic Routes to Quinoline Derivatives: Novel Syntheses of 3-Butyryl-8-methoxy-4-[(2-methylphenyl)amino]quinoline and 3-Butyryl-8-(2-hydroxyethoxy)-4-[(2-methylphenyl)amino]quinoline

Gary Francis GlaxoSmithKline Breen, J. Hayes, R. J. Atkins, 1997 .

Enzymatic resolution of a secondary amine using novel acylating reagents

Gary Francis GlaxoSmithKline Breen, 2004 .

A new synthesis of the GPIIb/IIIa receptor antagonist SB-214857-A

Gary Francis GlaxoSmithKline Breen, A. Wells, Stephen A. Smith, 2001 .

The Development of a Manufacturing Route for the GPIIb/IIIa Receptor Antagonist SB-214857-A. Part 1: Synthesis of the Key Intermediate 2,3,4,5-Tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic Acid Methyl Ester, SB-235349

Gary Francis GlaxoSmithKline Breen, A. Wells, Stephen A. Smith, 2003 .